Clinical Trial Detail

NCT ID NCT02531516
Title An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Aragon Pharmaceuticals, Inc.
Indications

prostate cancer

Therapies

Abiraterone + Apalutamide + Prednisone

Bicalutamide

Age Groups: adult

No variant requirements are available.